Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 39,800 shares at $56.22 ($2.3M) on 2024-08-14, disclosed to the SEC on 2024-08-15.
Scheduled sale ($2.3M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.25 | 10,000 | $563K | 24.7% |
| 2 | $56.22 | 3,263 | $183K | 8.1% |
| 3 | $56.22 | 3,263 | $183K | 8.1% |
| 4 | $57.73 | 6,537 | $377K | 16.6% |
| 5 | $57.73 | 6,537 | $377K | 16.6% |
| 6 | $58.17 | 200 |
| $12K |
| 0.5% |
| 7 | $57.95 | 10,000 | $580K | 25.5% |
| Total | $57.17 avg | 39,800 | $2.3M | 100% |
| Filing → |
| HALO | SELL | 2026-08-19 | $6.3M | — | Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |